目的 研究桂枝茯苓膠囊聯(lián)合米非司酮治療子宮肌瘤的療效及對患者血清孕激素受體（PR）、雌激素受體（ER）、血管內(nèi)皮生長因子（VEGF）的影響。方法 選取2014年1月-2017年6月西安市北方醫(yī)院婦產(chǎn)科收治的子宮肌瘤患者75例，隨機(jī)分為對照組、觀察組，各38、37例。對照組于月經(jīng)的第3天口服米非司酮片12.5 mg，每天1次，于每晚睡前口服；觀察組在對照組基礎(chǔ)上于月經(jīng)的第1天口服桂枝茯苓膠囊3粒，每天3次，療程3個(gè)月。比較兩組的臨床治療效果，比較兩組治療前后的子宮肌瘤體積、月經(jīng)量以及子宮體積，以及血清ER、PR、VEGF水平變化。結(jié)果 觀察組的有效率為94.59%（35/37），明顯高于對照組的71.05%（27/38），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療3個(gè)月后的子宮肌瘤體積、月經(jīng)量以及子宮體積均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且觀察組以上指標(biāo)明顯低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療3個(gè)月后的血清ER、PR、VEGF水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組以上指標(biāo)明顯低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。所有患者均未出現(xiàn)低血壓、體質(zhì)量顯著增加以及色素沉著等不良反應(yīng)。結(jié)論 桂枝茯苓膠囊聯(lián)合米非司酮對子宮肌瘤患者具有較為確切的治療效果，不僅可以有效縮小子宮肌瘤體積以及子宮體積，還可以降低血清ER、PR、VEGF水平。

Objective To investigate the clinical effect of Guizhi Fuling Pill on uterine myoma and its effect on serum ER, PR and VEGF. Methods Selected 75 cases of patients with uterine myoma who were treated in our hospital from January 2014 to December 2016, divided into two groups randomly. The control group was treated with Mifepristone Tablets 12.5 mg 1 times a day on the third day of menstruation. The observation group was treated with Guizhi Fuling Pill 3 times per day on the first day of menstruation, 3 times a day, comparing the clinical effect of two groups. Results After treatment, the effective rate of the observation group (94.59%) was significantly higher than that of the control group (71.05%) (P<0.05). The volume of uterine myoma, the amount of menstruation and the volume of uterus decreased significantly after 3 months of treatment (P<0.05), and the observation group was more obvious (P<0.05). The levels of serum ER, PR and VEGF in the two groups were significantly decreased after 3 months of treatment (P<0.05), and the observation group was more obvious (P<0.05). All patients had no adverse reactions such as hypotension, significant increase in weight, and pigmentation. Conclusions Guizhi Fuling Pill has a definite therapeutic effect for patients with uterine fibroids. It can not only effectively reduce the volume of uterine fibroids and uterine volume, but also reduce serum ER, PR and VEGF levels.